Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors

Molecular Cancer Research

Volumn 6, Issue 7, 2008, Pages 1137-1145

  Letard, Sébastien ^a,b,c,d   Yang, Ying ^a,b,c,d   Hanssens, Katia ^a,b,c,d,e   Palmérini, Fabienne ^a,b,c,d,e   Leventhal, Phillip S ^e   Guéry, Stéphanie ^a,b,c,d,e   Moussy, Alain ^e   Kinet, Jean Pierre ^g   Hermine, Olivier ^f   Dubreuil, Patrice ^a,b,c,d,e  

^a INSERM   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Centre de Référence des Mastocytoses AP HP Necker Enfants Malades   (France)

^e Association Francaise Initiatives Recherche Mastocytes Mastocytoses AFIRMM   (France)

^f IFR Necker   (France)

^g HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; STEM CELL FACTOR; 6,7 DIMETHOXY 3 PHENYLQUINOXALINE; 6,7-DIMETHOXY-3-PHENYLQUINOXALINE; LIGAND; MUTANT PROTEIN; PHOSPHOTYROSINE; SIGNAL PEPTIDE; STEM CELL FACTOR RECEPTOR; TYRPHOSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOG; DOSE RESPONSE; FEMALE; GENE EXPRESSION; GENE MUTATION; MALE; MASTOCYTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; ANIMAL DISEASE; CELL LINE; CHEMISTRY; DRUG EFFECT; EXTRACELLULAR SPACE; FLOW CYTOMETRY; GENETIC POLYMORPHISM; GENETICS; MASTOCYTOSIS; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE;

CANIS FAMILIARIS;

ANIMALS; CELL LINE; CELL PROLIFERATION; DOGS; EXTRACELLULAR SPACE; FEMALE; FLOW CYTOMETRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MALE; MASTOCYTOSIS; MICE; MUTANT PROTEINS; MUTATION; PHOSPHORYLATION; PHOSPHOTYROSINE; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; TYRPHOSTINS;

EID: 51649105768     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0067     Document Type: Article

References (34)

1. Roskoski R. Structure and regulation of KIT protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun 2005;338:1307-15.
2. Orfao A, Garcia-Montero AC, Sanchez L, Escribiano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30.
3. London CA, Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract 2003;33:473-89.
4. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 1973;14:27-40.
5. Riva F, Brizzola S, Stefanello D, Crema D, Turnin L. A study of mutations in the KIT gene of 232 dogs with mastocytoma. J Vet Diagn Invest 2005;17:385-8.
6. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Clustering of activating mutations in KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 1999;112:165-70.
7. Jones CL, Grahn RA, Chien MB, Lyons LA, London CA. Detection of KIT mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest 2004;16:95-100.
8. London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene KIT. Exp Hematol 1999;27:689-97.
9. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-68.
10. Kobie K, Kawabata M, Hioki K, et al. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. Res Vet Sci 2007;82:239-41.
11. Gleixner KV, Rebuzzi L, Mayerhofer M, et al. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 2007;35:1510-21.
12. Ueda S, Ikeda H, Mizuki M, et al. Constitutive activation of KIT by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. Int J Hematol 2002;76:427-35.
13. Kitayama H, Kanakura Y, Furitsu T, et al. Constitutively activating mutations of KIT receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995;85:790-8.
14. Warmuth M, Kim S, Gu XJ, Xia G, Adrián F. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 2007;19:55-60.
15. Emile JF, Théou N, Tabone S, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004;2:597-605.
16. Liao AT, Chien MB, Shenoy N, et al. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002;100:585-93.
17. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-4.
18. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002;39:529-35.
19. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 2006;8:104-11.
20. Kim TW, Lee H, Kang YK, et al. Prognostic significance of KIT mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004;10:3076-81.
21. Webster JD, Kiupel M, Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of KIT in canine cutaneous mast cell tumors. BMC Cancer 2006;6:85.
22. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of KIT tyrosine kinase. J Biol Chem 2004;279:31655-63.
23. Hartmann K, Wardelmann E, Ma Y, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005;129:1042-6.
24. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004;89:920-5.
25. Gari M, Goodeve A, Wilson G, et al. KIT proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999;105:894-900.
26. Zhang LY, Smith ML, Schultheis B, et al. A novel K509I mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373-8.
27. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007;130:323-34.
28. Roberts KG, Odell AF, Byrnes EM, et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007;6:1159-66.
29. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
30. Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002;16:2027-36.
31. Kovalenko M, Gazit A, Böhmer A, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res 1994;54:6106-14.
32. Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem 2003;278:4847-53.
33. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-74.
34. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 1988;18:97-104.